ESMO 2024 | BlissBio to Present Phase II Clinical Data of ADC BB-1701 at ESMO Congress 2024
Source:
|
Author:BlissBio
|
Published time: 2024-09-11
|
1706 Views
|
Share:
September 11, 2024 – BlissBio announces today the Phase II clinical data of antibody-drug conjugate (ADC) BB-1701 will be presented at the European Society for Medical Oncology (ESMO) Congress 2024, which will be held in Barcelona, Spain from September 13 to 17.
ESMO 2024 | BlissBio to Present Phase II Clinical Data of ADC BB-1701 at ESMO Congress 2024
September 11, 2024 – BlissBio announces today the Phase II clinical data of antibody-drug conjugate (ADC) BB-1701 will be presented at the European Society for Medical Oncology (ESMO) Congress 2024, which will be held in Barcelona, Spain from September 13 to 17.
Poster Title: A phase 2 study to evaluate the efficacy and safety of BB-1701 in advanced or metastatic NSCLC patients with HER2 mutation/amplification
Poster Board #: 1296P
Session Title: NSCLC, Metastatic
Onsite Poster display date: Saturday, September 14, 2024
At the same meeting, presentations for BB-1701 in previously-treated patients with HER2-positive or HER2-low unresectable or metastatic breast cancer (NCT06188559; Presentation: #437TiP) will also be made by Eisai Co., Ltd. (“Eisai”).
In 2023, BlissBio and Eisai entered into a clinical trial collaboration for BB-1701, and BlissBio commits to working with Eisai to advance the development of BB-1701 for the benefit of patients worldwide.
About BB-1701
BB-1701 is an innovative ADC developed by BlissBio consisting of anti-HER2 antibody and eribulin. It is designed to provide a safer and more effective treatment regimen for patients with locally advanced/metastatic HER2 expressing solid tumors and expected to have multiple market prospects for application in various tumor indications. BB-1701 has unique mechanism of action (MOA) including potent bystander effect and immunogenic cell death (ICD) activity. BB-1701 is currently in Phase II international clinical trials globally.
Media Inquiries
Bliss Biopharmaceutical Co., Ltd
TEL: +86-0571-86808367
E-mail: office@blissbiopharma.com
